Sign in Join
Daily desk

News

Artificial intelligence, technology, science, health and education — reported daily, with the original source attached to every item.

Topic All 🤖 Artificial Intelligence ⚡ Technology 🔭 Science 🩺 Health 🎓 Education 🌱 Climate & Energy 🚀 Space 📈 Policy & Business Sort

2 item(s)

A CD3×CD19 bispecific antibody bridges a patient's T cell and a B cell, with key trial results — 12 patients, 80% reaching low disease activity, 60% meeting remission criteria.
🩺 Health Study

Phase 1 Trial Finds a Cancer-Style T-Cell Engager Can Push Refractory Lupus Into Remission

A phase 1 trial of A-319, a CD3×CD19 bispecific antibody adapted from cancer therapy, pushed most of 12 treatment-resistant lupus patients …

EduFabTech · 2h ago · 4 min read
A bispecific antibody schematic bridges a T-cell and a myeloma cell, alongside headline stats showing 77.8% complete response, 92% two-year progression-free survival, and a hazard ratio of 0.15 for teclistamab.
🩺 Health Study

Randomized Trial Finds Teclistamab Outperforms Standard Early Treatment in High-Risk Smoldering Myeloma

A phase 2 trial in Nature Medicine found that early teclistamab treatment produced deep, durable remissions in high-risk smoldering myeloma…

EduFabTech · 1d ago · 4 min read